多发性硬化药物定价的定性研究:系统博弈
该研究通过对4名生物技术行业现任及前任高管的30分钟半结构化电话访谈,探讨多发性硬化疾病修正疗法的定价决策、理由与态度。结果显示初始定价由竞争对手价格决定,收入最大化和企业增长驱动涨价,国际定价差异和供应链扭曲也是重要因素,而回收研发成本并非主要理由。
要点
- 初始定价主要参照现有竞品价格。
- 收入最大化与企业增长驱动涨价。
- 回收研发成本对定价影响不强。
核心结论
- 现有价格生态、企业整体增长、国际定价差异和供应链扭曲可能比药物开发成本在多发性硬化药物定价决策中起更核心作用。
研究设计与样本
- 定性研究,对4名直接参与多发性硬化疾病修正疗法定价或营销的生物技术行业领袖进行30分钟半结构化电话访谈,由定性方法专家和主要研究者共同主持与分析,辅以预访谈在线调查。
主要发现
- 参与者一致表示初始价格决策由市场上现有竞争对手的价格决定。
- 在缺乏持续市场渗透的情况下,收入最大化和企业增长是涨价的驱动因素。
- 美国以外的较低收入预测也影响了定价策略。
- 药物分销和供应渠道日益复杂和影响力增大也被列为促成因素。
- 尽管涨价决策的动机是吸引未来创新投资,但回收药物特定研发成本作为理由并未被强烈认可对定价决策有显著影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe pricing decisions, justifications, and attitudes among current and former biotech industry executives for companies that manufacture multiple sclerosis disease-modifying therapies. METHODS: Four leaders in biotech who have been directly involved in multiple sclerosis disease-modifying therapy pricing or marketing volunteered to participate in 30-minute semistructured interviews conducted via telephone. An expert in qualitative methods moderated and analyzed the interviews alongside the principal investigator. Brief, preinterview online surveys were also administered to provide additional context and insight for discussion. Interviews were audio-recorded and professionally transcribed. RESULTS: Participants consistently stated that initial price decisions were dictated by the price of existing competitors in the market. Revenue maximization and corporate growth were drivers of price escalations in the absence of continued market penetration. Lower revenue predictions outside the United States also informed pricing strategies. The growing complexity and clout of drug distribution and supply channels were also cited as contributing factors. Although decisions to raise prices were motivated by the need to attract investment for future innovation, recouping drug-specific research and development costs as a justification was not strongly endorsed as having a significant influence on pricing decisions. CONCLUSIONS: Contrary to prevailing narratives that underscore drug development costs, findings from our interviews suggest that the existing price ecosystem, overall corporate growth, international pricing disparities, and supply chain-related distortions may play a more central role in drug pricing decision.
引用
- Hartung DM, Alley L, Johnston KA, et al. Qualitative study on the price of drugs for multiple sclerosis: Gaming the system. Neurology. 2019. PMID: 31767617. doi:10.1212/WNL.0000000000008653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。